<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The consistent presence of EBV genomes in certain <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> types (in particular, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-related central <z:mp ids='MP_0008912'>nervous</z:mp> system <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and nasopharyngeal <z:mp ids='MP_0002038'>carcinomas</z:mp>) may allow novel, EBV-based targeting strategies </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumors</z:e> contain the latent (transforming) form of <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>However, expression of either of the EBV immediate-early proteins, BZLF1 and BRLF1, is sufficient to induce lytic <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e>, resulting in <z:hpo ids='HP_0011420'>death</z:hpo> of the host cell </plain></SENT>
<SENT sid="3" pm="."><plain>We have constructed replication-deficient adenovirus vectors expressing the BZLF1 or BRLF1 immediate-early genes and examined their utility for killing latently infected <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells in vitro and in vivo </plain></SENT>
<SENT sid="4" pm="."><plain>We show that both the BZLF1 and BRLF1 vectors efficiently induce lytic <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> in Jijoye cells (an EBV-positive Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell line) </plain></SENT>
<SENT sid="5" pm="."><plain>Furthermore, lytic <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> converts the <z:chebi fb="4" ids="36044">antiviral drug</z:chebi>, <z:chebi fb="0" ids="465284">ganciclovir</z:chebi> (GCV), into a toxic (phosphorylated) form, which inhibits cellular as well as <z:mp ids='MP_0001799'>viral</z:mp> DNA polymerase </plain></SENT>
<SENT sid="6" pm="."><plain>When Jijoye cells are infected with the BZLF1 or BRLF1 adenovirus vectors in the presence of GCV, <z:mp ids='MP_0001799'>viral</z:mp> reactivation is induced, but virus replication is inhibited (thus preventing the release of infectious EBV particles); yet cells are still efficiently killed </plain></SENT>
<SENT sid="7" pm="."><plain>Finally, we demonstrate that the BZLF1 and BRLF1 adenovirus vectors induce lytic <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> when they are directly inoculated into Jijoye cell <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> grown in <z:hpo ids='HP_0004430'>severe combined immunodeficiency</z:hpo> mice </plain></SENT>
<SENT sid="8" pm="."><plain>These results suggest that induction of lytic <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, in combination with GCV, may be an effective strategy for treating EBV-associated <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
</text></document>